Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-15: Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma
NCT07227311Phase 2Recruiting
- Sponsor
- GSK
- Start
- Apr 2026
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Apr 2026; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07227311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227311.